Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer

por Beer, Tomasz M, Vogelzang, Nicholas, Bartůňková, Jiřina, Miller, Kurt, Oh, William, Oudard, Stephane, Pandha, Hardev, Sartor, A Oliver, Špíšek, Radek, Toole, Timothy O, Borgstein, Niels G, Gerritsen, Winald R
Publicado 2015